SN-40X

SN-40X is a first-in-class small molecule drug candidate developed for the treatment of diabetes and its complications, including cardiovascular disease and non-alcoholic steatohepatitis (NASH). It acts as a modulator of the SWELL1 (LRRC8A) chloride ion channel, targeting chloride ion-channel activity across multiple tissues to improve systemic metabolism. Preclinical studies have shown that related compounds such as SN-401 restore glycemic control, enhance insulin sensitivity and secretion, reduce hepatic steatosis/injury, and improve glucose uptake in adipose tissue and myocardium in diabetic mouse models. The therapeutic approach aims to address metabolic syndrome by restoring SWELL1 signaling in key organs involved in type 2 diabetes pathophysiology[1][2][3].